TMEM17 Promotes Tumor Progression in Glioblastoma by Activating the PI3K/AKT Pathway
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2908285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Shengyong Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Glioblastoma, Proto-Oncogene Proteins c-akt, Signal Transduction, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Glioblastoma (GBM) is a highly aggressive and fast-growing brain tumor, characterized by rapid progression, a very poor prognosis, and a high likelihood of recurrence. Thus, effective new therapeutic targets are urgently needed. Transmembrane proteins (TMEMs) have pro-cancer effects on multiple cancer types, but the mechanisms underlying the effects of TMEM17, particularly its role in GBM, remain unclear.
Methods
We conducted bioinformatics analyses and immunohistochemistry to evaluate the role of TMEM17 in a variety of cancer types. Functional assays were conducted included the Cell Counting Kit-8 assay, annexin V-FITC/PI double staining, 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay, wound healing assay, transwell invasion assay, and dual luciferase assay.
Results
We found that TMEM17 is associated with a poor prognosis in GBM. Prognostic analyses confirmed that high TMEM17 expression predicted poorer survival, establishing its significance as an independent prognostic factor. Functional assays demonstrated that silencing TMEM17 in GBM cell lines inhibited proliferation and invasion, and induced apoptosis, underscoring its role in tumor aggressiveness. From a mechanistic perspective, we discovered that the Ying Yang 1 (YY1) transcription factor can bind to the promoter of TMEM17, regulating its upregulation. Regarding downstream mechanisms, knocking down TMEM17 inhibited the phosphoinositide 3-kinase/AKT pathway. These findings suggest that TMEM17 plays a significant role in GBM and may be a potential therapeutic target for this cancer.
Conclusion
These data prove that TMEM17 plays a key role in the regulation of GBM and has great potential as a clinical therapeutic target for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurosurgery, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
- Department of the First Clinical Medical College, Guangxi Medical University, 530021 Nanning, Guangxi, China.
- Division of Spinal Orthopedics, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Zhou, Q., Yan, S., Liu, C., Li, F., Feng, D., & He, M. (2024). TMEM17 Promotes Tumor Progression in Glioblastoma by Activating the PI3K/AKT Pathway. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2908285
Vancouver
Wang S, Zhou Q, Yan S, Liu C, Li F, Feng D, et al. TMEM17 Promotes Tumor Progression in Glioblastoma by Activating the PI3K/AKT Pathway. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2908285
BibTeX
@article{Wang2024,
author = {Wang, Shengyong and Zhou, Quan and Yan, Sheng and Liu, Chang and Li, Fujun and Feng, Daqin and He, Maolin},
title = {TMEM17 Promotes Tumor Progression in Glioblastoma by Activating the PI3K/AKT Pathway},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2908285}
}
EUVIMED